Welcome to our dedicated page for Gaxos.AI SEC filings (Ticker: GXAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Curious how Gaxos.AI turns empathetic code into revenue? Start with the fundamentals in the Gaxos.AI annual report 10-K simplified and the Gaxos.AI quarterly earnings report 10-Q filing. These dense disclosures cover R&D outlays for its wellness algorithms and licensing income from Gaxos Labs—yet most readers just want the highlights. That’s why Stock Titan delivers Gaxos.AI SEC filings explained simply, extracting segment revenue, subscription churn, and capitalized software costs so you can focus on decisions, not page counts.
Our platform streams Gaxos.AI Form 4 insider transactions real-time, letting you spot patterns in Gaxos.AI insider trading Form 4 transactions minutes after executives act. Need context? AI-powered dashboards provide Gaxos.AI earnings report filing analysis and charts that transform footnotes into clear trends. Whether you’re understanding Gaxos.AI SEC documents with AI or reviewing the latest Gaxos.AI 8-K material events explained, every filing arrives seconds after it hits EDGAR, already summarized and tagged.
Investors use these insights to monitor Gaxos.AI executive stock transactions Form 4, benchmark R&D intensity, and decode the Gaxos.AI proxy statement executive compensation for alignment with shareholder value. Stop hunting through PDFs—Stock Titan’s AI highlights contract wins, partnership announcements, and deferred-revenue shifts in a fraction of the time. From real-time alerts to intuitive summaries, every Gaxos.AI disclosure is organized for quick, confident analysis.
Gaxos.ai Inc. held its 2025 annual meeting of stockholders with 2,538,104 shares represented, constituting a quorum. All four director nominees were elected to serve until the next annual meeting; For votes for the nominees ranged from 592,411 to 609,602, with 1,905,954 broker non-votes recorded on the director elections. Stockholders ratified the appointment of Salberg & Company, P.A. as the independent auditor for fiscal 2025 by a vote of 2,274,665 For, 246,475 Against, and 16,964 Abstain. Shareholders also approved an amendment to the 2022 Omnibus Equity Incentive Plan to increase reserved shares from 553,637 to 803,637; the vote on the amendment was 507,255 For, 122,893 Against, 2,002 Abstain, with 1,905,954 broker non-votes.
Gaxos.ai reported initial commercial revenue while continuing product investments and recording operating losses. Revenue was $170,971 in Q2 2025 and $194,703 for the six months, driven primarily by RNK Health administrative services ($170,398 Q2; $192,950 six months). The company recorded a net loss of $824,572 for the quarter and $2,056,634 year-to-date, driven by research and development and general and administrative costs of $1,153,665 in Q2.
On the balance sheet, cash declined to $1,718,964 from $14,398,099 at December 31, 2024, after purchasing short-term investments that rose to $12,326,666. Working capital remained positive at $13,992,440, and management states these resources should be sufficient to meet operating needs for the next 12 months. The company recorded a $748,000 intangible asset acquisition funded with $500,000 cash and 200,000 shares valued at $248,000.
FAQ
What is the current stock price of Gaxos.AI (GXAI)?
What is the market cap of Gaxos.AI (GXAI)?
